VWF anticorps (AA 1815-1939)
Aperçu rapide pour VWF anticorps (AA 1815-1939) (ABIN6251948)
Antigène
Voir toutes VWF AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Épitope
- AA 1815-1939
-
Purification
- Protein G affinity chromatography
-
Immunogène
- Amino acids 1815-1939 from the human protein were used as the immunogen for this vWF antibody.
-
Isotype
- IgG2b kappa
-
-
-
-
Indications d'application
-
Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT
The optimal dilution of the vWF antibody for each application should be determined by the researcher. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- PBS with 0.1 mg/mL BSA and 0.05 % sodium azide
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Aliquot and Store at -20C. Avoid freez-thaw cycles.
-
-
- VWF (Von Willebrand Factor (VWF))
-
Autre désignation
- von Willebrand Factor / vWF
-
Sujet
- Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.
-
ID gène
- 7450
-
UniProt
- P04275
Antigène
-